Enovis is emerging from a post-acquisition trough, with gross margin expanding to 61.6% in 2026Q2 and operating margin turning positive at 3.0%, signaling operational stabilization.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.88+14.7% vs $0.77 | $559M+0.3% vs $557M |
Q3 2026 Aug 6, 2026 | $0.90+6.3% vs $0.85 | $583M+0.2% vs $582M |
Q2 2026 May 7, 2026 | $0.89+8.5% vs $0.82 | $589M+3.0% vs $572M |
Q1 2026 Feb 26, 2026 | $0.95+17.3% vs $0.81 | $576M-1.2% vs $583M |
Enovis NYSE: ENOV reported third-quarter sales of $559 million and raised its full-year adjusted earnings outlook, as growth in its reconstructive business and improved cash generation helped offset what executives described as a volatile market for medical procedures.
Enovis Corporation ( ENOV ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Kyle Rose - Vice President of Investor Relations Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Ross Osborn - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Vikramjeet Chopra - BMO Capital Markets Equity Research Steven Lichtman - William Blair & Company L.L.C.
Enovis (ENOV) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.
Dallas, TX, Nov. 05, 2026 (GLOBE NEWSWIRE) -- - Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 2, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Benchmark ENOV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Enovis Corporation (ENOV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.16 | $1.56B | -3.01 | 6.66% | -22.87% | -35.48% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $80.89 | $1.85B | 29.47 | 13.53% | 23.51% | 15.33% | 0.98% | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% |
Enovis Corporation (ENOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Enovis Corporation (ENOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 19, 2026·SEC
May 7, 2026·SEC
Get notified when ENOV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Enovis Corporation (ENOV) stock FAQ — growth, dividends, profitability & financials explained
Enovis Corporation (ENOV) reported $2.31B in revenue over the trailing twelve months. Revenue was $2.25B in fiscal year 2025. That is 551% more than the $345.5M of fiscal year 2005.
Enovis Corporation (ENOV) grew revenue by 3.3% over the trailing twelve months, compared with the twelve months before.
No. Enovis Corporation (ENOV) reported a net loss of $527.4M over the trailing twelve months.
Enovis Corporation (ENOV) had a return on equity (ROE) of -35.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Enovis Corporation (ENOV) generated $69.6M in free cash flow over the trailing twelve months.
